Therapeutic uses of .beta.-casein a2 and dietary supplement containing .beta.-casein a2
CA 2500530 C · Owner: Tailford, Kristy Ann · Inventors: Mclachlan, Corran Normann Stuart; Campbell, Julie Hazel; Tailford, Kristy Ann
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of reducing the serum level in a mammal of any one more cholesterol low density lipoprotein (LDL) cholesterol relative to high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol very low density , lipoprotein (VLDL) cholesterol apolipoprotein B, and triglycerides by the ingestion of a composition containing .beta.-casein A2. A dietary supplement formed by the addition of .beta.-casein to a food or drink for human consumption where the .beta.-casein is comprised of at least 95% .beta.-casein A2, preferably solely .beta.-casein A2.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 3, 2003 and granted January 8, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 3, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 3, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.